SMARCA4 and colonic neoplasm: On univariate analysis, patients whose localized colon tumors were BRG1-moderate/strong had a significantly lower overall survival (OS) than those with BRG1-negative/weak tumors (Table 2, hazard ratio [HR]: 2.494, 95% confidence interval [CI]: 1.564–3.975, P < 0.001).